EULAV Asset Management lowered its position in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) by 31.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 450,000 shares of the biopharmaceutical company’s stock after selling 210,000 shares during the quarter. EULAV Asset Management’s holdings in Intercept Pharmaceuticals were worth $7,331,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. Ensign Peak Advisors Inc acquired a new position in Intercept Pharmaceuticals during the 4th quarter worth approximately $180,000. Invesco Ltd. lifted its position in Intercept Pharmaceuticals by 17.6% during the 3rd quarter. Invesco Ltd. now owns 14,058 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 2,107 shares in the last quarter. WINTON GROUP Ltd acquired a new position in Intercept Pharmaceuticals during the 4th quarter worth approximately $226,000. Hollencrest Capital Management acquired a new position in Intercept Pharmaceuticals during the 4th quarter worth approximately $244,000. Finally, Prospera Financial Services Inc raised its position in shares of Intercept Pharmaceuticals by 45.8% in the 3rd quarter. Prospera Financial Services Inc now owns 19,953 shares of the biopharmaceutical company’s stock valued at $296,000 after purchasing an additional 6,267 shares in the last quarter. Institutional investors and hedge funds own 83.44% of the company’s stock.
ICPT has been the topic of a number of recent analyst reports. Royal Bank of Canada cut their target price on Intercept Pharmaceuticals from $22.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Thursday, March 3rd. Needham & Company LLC cut their target price on Intercept Pharmaceuticals from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $14.00 target price on the stock in a research report on Monday, March 7th. Canaccord Genuity Group cut their target price on Intercept Pharmaceuticals from $31.00 to $29.00 and set a “hold” rating on the stock in a research report on Tuesday, March 8th. Finally, StockNews.com assumed coverage on Intercept Pharmaceuticals in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Intercept Pharmaceuticals currently has an average rating of “Hold” and an average price target of $27.23.
Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) last issued its quarterly earnings data on Friday, May 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.31. During the same period in the prior year, the company earned ($1.22) EPS. On average, analysts forecast that Intercept Pharmaceuticals, Inc. will post -2.71 earnings per share for the current year.
Intercept Pharmaceuticals Company Profile (Get Rating)
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.
- Get a free copy of the StockNews.com research report on Intercept Pharmaceuticals (ICPT)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.